Sitravatinib

司曲替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameSitravatinib
Drug Alias NameSitravatinibum西屈替尼Sitravatinib malate苹果酸Sitravatinib西曲替尼 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonists +[10] 
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Vascular endothelial growth factor receptor 2 +[10] 
Therapy Area/IndicationsUveal melanomaMetastatic breast cancerOral Squamous Cell Carcinoma +[24] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMirati Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyMirati Therapeutics IncColumbia University +[9] 
Inactive CompaniesUniversity Health Network (Uhn)
Active IndicationsUveal melanomaMetastatic breast cancerSolid tumours +[12] 
Inactive IndicationsOral Squamous Cell CarcinomaLung DiseasesUreteral Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG